Navigation Links
Disability System Sorely in Need of Reform
Date:9/27/2007

are only made by the applicant, not Social Security, the number can

only go up, never down, during the appeals process.

Chile replaced its traditional social security system 25 years ago with a system of personal retirement accounts. Workers now put 10 percent of their wages into personal retirement accounts in pension funds of their choice and pay an additional 2.4 percent for survivors' and disability insurance and administrative fees.

Depending on the number of years they have participated and the degree of their disability, Chilean workers are guaranteed to receive as much as 70 percent of their wages -- a higher percentage than disabled workers in the U.S. Although workers have a lifetime to save for retirement, they can become disabled at any age. If a disabled worker's retirement account balance is insufficient to purchase an annuity that replaces a guaranteed percentage of his wages, he receives the rest from a group insurance policy purchased by the worker's pension fund. On the average, workers' own savings are projected to cover about 50 percent of the cost of their disability benefits; insurance covers the rest. Due to this reform, Chile's disability system will cost only a fourth of what it otherwise would have been, in the long run.

According to the NCPA's study, several features of Chile's disability system reduce costs and provide workers with incentives to continue working. For example:

-- Part of the benefit is financed by the worker's retirement account and

investment earnings on the annuity premium.

-- Since disabled workers draw on their own retirement accounts to fund

their benefits, workers have less of an incentive to claim disability

as a form of early retirement.

-- Pension funds in Chile participate in the disability assessment

procedure and can challenge disability determinations made by

independent medical boards.

-- Once workers in Chile
'/>"/>

SOURCE National Center for Policy Analysis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alcoholics are prone to disability
2. Hypertension drugs could lower Disability
3. Running delays disability in the aged
4. Restricted Activity Predicts Disability
5. Obesity More Likely to Cause Disability than Death in Elderly
6. Kalam Appeals to Eradicate Hearing Disability
7. Psychosocial Disability Varies In Accordance With Bipolar Symptom Changes
8. Depression And Chronic Pain Cause Disability In Women
9. The higher the income the lower the disability rates!
10. Life expectancy has increased… so has the disability rates!
11. Preventing Falls May Be Key to Avoiding Disability in Elderly

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, CHICA...nited States House of Representatives passed by a ...lation that would strengthen Medicare for seniors ... prices millions of Americans out of affordable he...
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, BALTI... Tonight the United States House of Representative...hat would strengthen Medicare for seniors and end ...millions of Americans out of affordable health cov...
(Date:11/7/2009)...ON, Nov. 7 Karen Ignagn... Plans (AHIP), released the following statement to...lans strongly support comprehensive health care re...y proposing a complete overhaul of how health insu...guaranteed coverage, elimination of pre-existing c...
(Date:11/7/2009)... Nov. 7, The American M...njamin Rush Award for Citizenship and Community Se...from Chicago, IL. The award recognizes physicians ...call of duty to make an outstanding public service...received the award today during the opening sessio...
(Date:11/7/2009)...yn T. Coleman (CT), David A. Cook (GA), Louis J. G... (LA) Honored ,, CHICAGO, Nov. 7 /PRNewswire-U...A) today presented five medical society executive ...tributions to the goals and ideals of the medical ... semi-annual policy making meeting in Houston. ,...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA Honors Medical Society Executives 2
...he Prescription Drug User Fee Act (PDUFA) user fee...ry 18, 2008 -, YARDLEY, Pa., Sept. 20 Tibotec Ph...ug Application (NDA) for TMC125,(etravirine), an i...stration (FDA). The Prescription Drug User Fee,Act...
...LIN, N.J., Sept. 20 SyntheMed, Inc. (OTC,Bulletin...he development,and commercialization of anti-adhes...t the Circulatory System Devices Advisory Panel of...,likely to need secondary open heart surgery. The ...
...phyX(TM) receives FDA clearance, REDMOND, Wash., ... EsophyX(TM) device for performing Transoral Incis...ing gastroesophageal reflux,disease has received F...pleted yesterday under general anesthesia,transora...
...BOSTON Since the days of Hippocrates, people have ...seasons. More recently, researchers have learned t...seasonality, are often related to the weather. In ... Department of Public Heath and Family Medicine at...
...(Washington) Expressions of deep concern and disa...authorization will go forward without addressing s...for Medicare beneficiaries were sent today to cong...nal medicine physicians and medical student member...
...ndation Duped By Overseas Supplier, WAKEFIELD, Ma...tion established to support cancer-fighting resear...ng due to high lead levels the jewelry it,distribu... contain lead. When Friends of Mel recently learne...
Other Medicine News:Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 2Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 3Health News:FDA Panel Recommends Approval of SyntheMed's REPEL-CV(R) Adhesion Barrier for Pediatric Patients 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 3Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 4Health News:Mathematics might save you a trip to the ER 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 3Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 2Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 3
(Date:11/6/2009)..., Nov. 6 Caraco Pharmace...aunched ketorolac tromethamine ophthalmic solution... and Drug Administration (FDA) for Sun Pharma,s Ab...Acular® opthalmic solution on the first day f...olac is therapeutically equivalent to Acular®...
(Date:11/6/2009)...IS, November 6 , - Trial ...lid for the,Treatment of Multi-Resistant Staphyloc... a speciality pharmaceutical company focused on th...esigned to overcome the significant global,problem... most advanced oral,antibacterial NXL103 (floprist...
(Date:11/5/2009)...GO, Nov. 5 Althea Technologies, I...turing services for biopharmaceutical products ann...lopment to the company,s platform of services, whi...es Matsuura, Director of Formulation Development. ...ion and analytical scientists, along with new labo...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Partnership to accelerate Trudeau Institute discoveries to patient care 8711 1Partnership to accelerate Trudeau Institute discoveries to patient care 8711 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 1Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 3WWII Veterans Compete in National Veterans Golden Age Games 47813 1WWII Veterans Compete in National Veterans Golden Age Games 47813 2
...NTA, Dec. 11 The Arthritis Foundation,the leading...llion,Americans living with arthritis, today annou...eters of Enbrel (R) (etanercept), will be the,nati... (R)., "The Arthritis Foundation hosts hundreds o...to prevent, control and cure arthritis, the,nation...
...CETON, N.J. and FOSTER CITY, Calif., Dec. 11 /PRNe...(NYSE: BMY ) and Gilead Sciences, Inc.,(Nasdaq: ...ze ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 ... for the treatment of virologically suppressed adu... approval by the European,Commission. If approved,...
Other Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8
Assay Development
Custom Conjugation
Iso-Electric Determination Kit
Rabbit Anti-Goat IgG (H & L) Antibody, Colloidal Gold Conjugated, 50 OD
Medicine Products: